Julphar was established in 1980 under the guidance of His Highness Sheikh Saqr Bin Mohammed Al Qasimi. By 1984, the company had obtained approval to sell 30 pharmaceutical products to the market. Over the years that followed, Julphar launched numerous additional medicines as well as a range of holistic and diabetes solutions.
Today, the company is a household name in the UAE and one of the largest pharmaceutical manufacturers in the Middle East and Africa.
Through its three core business divisions, diabetes solutions, general medicines, and direct-to-consumer, Julphar’s pharmaceuticals target a number of key therapeutic areas, including the gastrointestinal tract (GIT), respiratory, pain management, wounds and scars, anti-infectives, anaemia, gynaecology, dermatology, erectile dysfunction, and cardiology.
In its commitment to clinical excellence, Julphar also runs a division dedicated to pharmacovigilance – the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.
Julphar continually assesses new and emerging safety data as it becomes available and undertakes regulatory action as required. In addition to contributing to the safety profiles of existing drugs, these pharmacovigilance activities help to improve the knowledge set and contribute to the breadth of available epidemiological data.
To serve this vast international market, the company employs 2,500 people and distributes products to more than 50 countries on five continents. Across its 13 internationally accredited facilities in Africa and the Middle East, Julphar produces over a million boxes of medicine a day.
This colossal output saw the company become one of the world’s largest producers of insulin in 2012, thanks to its state-of-the-art UAE-based biotechnology facility.
Having expanded from its Ras Al Khaimah base into Saudi Arabia, Julphar’s growth story shows no signs of slowing. In 2022, the company reported a 41% increase in year-on-year revenue, reaching USD 440m.
